Compounds > adriamycinol

Page last updated: 2024-08-25

adriamycinol and Breast Cancer

adriamycinol has been researched along with Breast Cancer in 17 studies

Research

Studies (17)

Timeframe	Studies, this research(%)	All Research%
pre-1990	3 (17.65)	18.7374
1990's	3 (17.65)	18.2507
2000's	5 (29.41)	29.6817
2010's	5 (29.41)	24.3611
2020's	1 (5.88)	2.80

Authors

Authors	Studies
de Andrade, JM; Lanchote, VL; Oliveira, ML; Pippa, LF; Rocha, A	1
Chai, H; Jing, W; Liang, C; Tu, J; Yu, M; Yu, Y; Zhu, M; Zuo, J	1
Harada, N; Inui, H; Isayama, A; Ito, Y; Mitani, T; Nakano, Y; Takenaka, S; Tanimori, S; Yamaji, R	1
Ashida, H; Harada, N; Inui, H; Ito, Y; Mitani, T; Nakano, Y; Yamaji, R	1
Blaes, A; Brundage, RC; Jacobson, PA; Kirstein, MN; Liang, S	1
Gavelová, M; Hladíková, J; Krcmár, P; Machala, M; Novotná, R; Skálová, L; Vildová, L; Vondrácek, J	1
Guo, B; Heibein, AD; Maclean, DA; Parissenti, AM; Sprowl, JA	1
Batist, G; Bhamra, R; Bolcsak, LE; Boxenbaum, H; Chaikin, P; Chow, SC; Guthrie, TH; Swenson, CE; Tkaczuk, KH; Welles, L	1
Brown, AM; Bryant, J; Dakhil, SR; Davidson, NE; Fehrenbacher, L; Geyer, CE; Ingle, JN; Jenkins, RB; Kaufman, PA; Klein, PM; Kutteh, LA; Lingle, WL; Mamounas, EP; Martino, S; Paik, S; Perez, EA; Pisansky, TM; Romond, EH; Suman, VJ; Swain, SM; Tan-Chiu, E; Visscher, DW; Vogel, VG; Wolmark, N; Yothers, G	1
Ang, PC; Chen Shu, X; Chowbay, B; Figg, WD; Jada, SR; Lal, S; Lee, EJ; Wong, ZW; Xiang, X	1
Boumendjel, A; Ehrlichová, M; Gut, I; Kondrová, E; Kovár, J; Soucek, P; Stopka, P; Václavíková, R	1
Collins, JM; Greene, RF; Jenkins, JF; Myers, CE; Speyer, JL	1
Bergerat, JP; Duclos, B; Dufour, P; Levêque, D; Limacher, JM; Methlin, G; Wihlm, J	1
Aldhous, M; Dobbs, NA; Harper, PG; Richards, MA; Rubens, RD; Twelves, CJ	1
Bronchud, MH; Howell, A; Lind, M; Lucas, SB; Margison, JM; Wilkinson, PM	1
François, E; Frenay, M; Khater, R; Milano, G; Namer, M; Pons, D; Renee, N; Thyss, A	1
Brockmann, B; Hüller, H; Matthias, M; Preiss, R; Sohr, R	1

Trials

3 trial(s) available for adriamycinol and Breast Cancer

Article	Year
Pharmacokinetic-pharmacodynamic modelling of acute N-terminal pro B-type natriuretic peptide after doxorubicin infusion in breast cancer. British journal of clinical pharmacology, 2016, Volume: 82, Issue:3 Topics: Adult; Antibiotics, Antineoplastic; Biomarkers; Breast Neoplasms; Doxorubicin; Female; Humans; Middle Aged; Models, Biological; Natriuretic Peptide, Brain; Peptide Fragments; Troponin	2016
Pharmacokinetics of doxorubicin administered i.v. as Myocet (TLC D-99; liposome-encapsulated doxorubicin citrate) compared with conventional doxorubicin when given in combination with cyclophosphamide in patients with metastatic breast cancer. Anti-cancer drugs, 2003, Volume: 14, Issue:3 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Breast Neoplasms; Chromatography, High Pressure Liquid; Clinical Trials, Phase III as Topic; Cyclophosphamide; Doxorubicin; Female; Half-Life; Humans; Infusions, Intravenous; Leukocyte Count; Liposomes; Metabolic Clearance Rate; Middle Aged; Neoplasm Metastasis	2003
Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. The New England journal of medicine, 2005, Oct-20, Volume: 353, Issue:16 Topics: Adult; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Cyclophosphamide; Disease-Free Survival; Doxorubicin; Female; Heart Diseases; Humans; Mastectomy; Middle Aged; Paclitaxel; Proportional Hazards Models; Receptor, ErbB-2; Recurrence; Survival Analysis; Trastuzumab	2005

Other Studies

14 other study(ies) available for adriamycinol and Breast Cancer

Article	Year
Total, renal and hepatic clearances of doxorubicin and formation clearance of doxorubicinol in patients with breast cancer: Estimation of doxorubicin hepatic extraction ratio. Journal of pharmaceutical and biomedical analysis, 2020, Jun-05, Volume: 185 Topics: Adult; Antineoplastic Agents; Area Under Curve; Biological Variation, Population; Breast Neoplasms; Cardiomyopathies; Chemotherapy, Adjuvant; Chromatography, High Pressure Liquid; Doxorubicin; Female; Hepatobiliary Elimination; Humans; Kidney; Liver; Mastectomy; Middle Aged; Neoadjuvant Therapy; Renal Elimination; Tandem Mass Spectrometry	2020
Inhibition of miR-155, a therapeutic target for breast cancer, prevented in cancer stem cell formation. Cancer biomarkers : section A of Disease markers, 2018, Feb-06, Volume: 21, Issue:2 Topics: Animals; Breast Neoplasms; Cell Line, Tumor; Cell Proliferation; Doxorubicin; Female; Gene Expression; Heterografts; Humans; Mice; Mice, Inbred BALB C; Mice, Nude; MicroRNAs; Neoplastic Stem Cells; Transfection	2018
Identification of carbonyl reductase 1 as a resveratrol-binding protein by affinity chromatography using 4'-amino-3,5-dihydroxy-trans-stilbene. Journal of nutritional science and vitaminology, 2013, Volume: 59, Issue:4 Topics: Alcohol Oxidoreductases; Antibiotics, Antineoplastic; Antineoplastic Agents, Phytogenic; Binding, Competitive; Breast Neoplasms; Chromatography, Affinity; Doxorubicin; Female; Humans; Hydroquinones; MCF-7 Cells; NADP; Phytotherapy; Plant Extracts; Protein Binding; Resveratrol; Stilbenes	2013
Resveratrol reduces the hypoxia-induced resistance to doxorubicin in breast cancer cells. Journal of nutritional science and vitaminology, 2014, Volume: 60, Issue:2 Topics: Alcohol Oxidoreductases; Antineoplastic Agents; Breast Neoplasms; Doxorubicin; Drug Resistance, Neoplasm; Female; Humans; Hypoxia; Hypoxia-Inducible Factor 1, alpha Subunit; Leupeptins; MCF-7 Cells; Phytotherapy; Plant Extracts; Resveratrol; RNA, Messenger; Stilbenes	2014
Reduction of doxorubicin and oracin and induction of carbonyl reductase in human breast carcinoma MCF-7 cells. Chemico-biological interactions, 2008, Oct-22, Volume: 176, Issue:1 Topics: 3-Hydroxysteroid Dehydrogenases; Alcohol Oxidoreductases; Aldehyde Reductase; Aldo-Keto Reductase Family 1 Member C3; Aldo-Keto Reductases; Biotransformation; Blotting, Western; Breast Neoplasms; Cell Line, Tumor; Dose-Response Relationship, Drug; Doxorubicin; Enzyme Induction; Enzyme Inhibitors; Ethanolamines; Gene Expression Regulation, Neoplastic; Humans; Hydroxyprostaglandin Dehydrogenases; Isoquinolines; Kinetics; Methacrylates; Oxidation-Reduction; Phenylpropionates; Quercetin; RNA, Messenger; Subcellular Fractions	2008
Role of aldo-keto reductases and other doxorubicin pharmacokinetic genes in doxorubicin resistance, DNA binding, and subcellular localization. BMC cancer, 2012, Aug-31, Volume: 12 Topics: 20-Hydroxysteroid Dehydrogenases; 3-Hydroxysteroid Dehydrogenases; Aldehyde Reductase; Aldo-Keto Reductase Family 1 Member C3; Aldo-Keto Reductases; Breast Neoplasms; Cell Nucleus; Cholic Acids; Cyclosporine; DNA, Neoplasm; Doxorubicin; Drug Resistance, Neoplasm; Gene Expression Profiling; Humans; Hydroxyprostaglandin Dehydrogenases; Intracellular Space; MCF-7 Cells; Oligonucleotide Array Sequence Analysis	2012
Novel SLC22A16 polymorphisms and influence on doxorubicin pharmacokinetics in Asian breast cancer patients. Pharmacogenomics, 2007, Volume: 8, Issue:6 Topics: Adult; Aged; Asian People; Breast Neoplasms; Doxorubicin; Female; Gene Frequency; Genetic Variation; Humans; Middle Aged; Organic Cation Transport Proteins; Polymorphism, Genetic	2007
The effect of flavonoid derivatives on doxorubicin transport and metabolism. Bioorganic & medicinal chemistry, 2008, Feb-15, Volume: 16, Issue:4 Topics: Antibiotics, Antineoplastic; Benzofurans; Biological Transport; Breast Neoplasms; Cell Line, Tumor; Doxorubicin; Female; Flavonoids; Humans; Metabolism; Quercetin	2008
Plasma pharmacokinetics of adriamycin and adriamycinol: implications for the design of in vitro experiments and treatment protocols. Cancer research, 1983, Volume: 43, Issue:7 Topics: Acetylcysteine; Breast Neoplasms; Chromatography, High Pressure Liquid; Doxorubicin; Drug Administration Schedule; Half-Life; Humans; Infusions, Parenteral; Kinetics; Mathematics; Research Design	1983
[Pharmacokinetic profile of high-dose doxorubicin administered during a 6 h intravenous infusion in breast cancer patients]. Bulletin du cancer, 1997, Volume: 84, Issue:6 Topics: Adult; Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclophosphamide; Doxorubicin; Drug Administration Schedule; Female; Granulocyte Colony-Stimulating Factor; Granulocyte-Macrophage Colony-Stimulating Factor; Half-Life; Humans; Metabolic Clearance Rate; Middle Aged; Treatment Outcome	1997
Comparative pharmacokinetics of doxorubicin given by three different schedules with equal dose intensity in patients with breast cancer. Cancer chemotherapy and pharmacology, 1991, Volume: 28, Issue:4 Topics: Breast Neoplasms; Chromatography, High Pressure Liquid; Dose-Response Relationship, Drug; Doxorubicin; Female; Humans; Infusions, Intravenous; Injections, Intravenous; Neoplasm Metastasis; Time Factors	1991
Comparative pharmacokinetics of escalating doses of doxorubicin in patients with metastatic breast cancer. Cancer chemotherapy and pharmacology, 1990, Volume: 25, Issue:6 Topics: Adult; Breast Neoplasms; Chromatography, High Pressure Liquid; Dose-Response Relationship, Drug; Doxorubicin; Female; Half-Life; Humans; Metabolic Clearance Rate; Middle Aged; Naphthacenes	1990
Pharmacokinetics of weekly low dose doxorubicin. European journal of cancer & clinical oncology, 1989, Volume: 25, Issue:2 Topics: Adult; Aged; Aged, 80 and over; Bilirubin; Breast Neoplasms; Doxorubicin; Female; Half-Life; Humans; Middle Aged; Time Factors	1989
Pharmacokinetics of adriamycin, adriamycinol, and antipyrine in patients with moderate tumor involvement of the liver. Journal of cancer research and clinical oncology, 1987, Volume: 113, Issue:6 Topics: Adult; Antipyrine; Breast Neoplasms; Carcinoma, Hepatocellular; Doxorubicin; Female; Humans; Liver Function Tests; Liver Neoplasms; Male; Metabolic Clearance Rate; Middle Aged	1987